Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 2, 2006

New Schering-Plough Facility More than Doubles Staffing Capacity and Triples Lab Space

  • Schering-Plough has dedicated a new scientific research facility in Cambridge, MA to support its discovery and development of  innovative therapeutic treatments. This larger facility has been set up for Cambridge scientists in Schering-Plough Research Institute (SPRI).

    The laboratory facility provides capacity for approximately 200 scientists and support staff, up from about 80 at the prior Cambridge location, and more than triple the amount of laboratory space.

    Focusing on the early stages of the drug discovery process, SPRI Cambridge conducts research to develop a portfolio of small molecule drugs and provide efficiency in lead discovery through the use of affinity-based screening technologies and an integrated chemistry library.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »